Skip to content
2000
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
side by side viewer icon HTML

Abstract

HIV and Tuberculosis (TB) are the leading global causes of death among patients with infectious diseases. They contribute significantly to morbidity around the world because of their impact on shared immune defense mechanisms. Tuberculosis is an infection that exploits the vulnerability of compromised immune systems. Opportunistic infections are illnesses that are more frequent or severe in individuals with compromised immune systems. HIV weakens the immune system, making people more susceptible to tuberculosis. When someone is infected with both HIV and tuberculosis, this is known as HIV/TB coinfection. HIV and tuberculosis represent the primary infectious disease challenges in countries with limited resources. In affected individuals, the interaction between Mycobacterium tuberculosis and HIV exacerbates the effects of each other, hastening the decline of immune function and leading to premature mortality if left untreated. Individuals with HIV are more likely than those without HIV to develop active tuberculosis as a result of untreated latent tuberculosis. Antiretroviral therapy (ART) is the use of HIV medications to protect the immune system and prevent the progression of HIV to acquired immunodeficiency syndrome (AIDS). In people with HIV and latent tuberculosis, combined treatment with HIV and TB medications reduces the likelihood of latent tuberculosis progressing to active tuberculosis. The purpose of this research is to understand better the pathogenesis and pathways of HIV/TB co-infection, as well as to investigate drug-drug interactions in multi-drug therapies.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X324303241009061805
2024-12-03
2025-08-13

  • From This Site

    /content/journals/cis/10.2174/012210299X324303241009061805
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. BellL.C.K. NoursadeghiM. Pathogenesis of HIV-1 and mycobacterium tuberculosis co-infectionNat Rev Microbiol2018162809010.1038/nrmicro.2017.128
     [Google Scholar]
  2. CohnD. GrayJ. Tuberculosis and HIV coinfection.Semin. Respir. Crit. Care Med.201334103204310.1055/s‑0032‑133346923460004
     [Google Scholar]
  3. HIV and TB2021Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-tuberculosis-tb
    [Google Scholar]
  4. Global tuberculosis report 2023.2023Available: https://iris.who.int/
  5. Global Tuberculosis report 2022.2022Available: http://apps.who.int/bookorders
  6. Global tuberculosis report 2020.2020Available from: https://www.who.int/publications/i/item/9789240013131 World Health Organization
  7. TB/HIV: A Clinical Manual.2004Available from: https://www.who.int/publications/i/item/9241546344 2nd ed
  8. RewariB.B. KumarA. MandalP.P. PuriA.K. HIV TB coinfection - perspectives from IndiaExpert Rev Respir Med.202115791193010.1080/17476348.2021.1921577
     [Google Scholar]
  9. WongK. Pathogenesis of human immunodeficiency virus-mycobacterium tuberculosis co-infectionJ Clin Med.202091112310.3390/jcm9113575
     [Google Scholar]
  10. Azevedo-PereiraJ. M. PiresD. CaladoM. MandalM. Santos-CostaQ. AnesE. HIV/Mtb Co-Infection: From the amplification of disease pathogenesis to an ‘emerging syndemic,’Microorganisms.202311485310.3390/microorganisms11040853
     [Google Scholar]
  11. AntonyB. TiewsohJ.B.A. BoloorR. HIV-TB co-infection with clinical presentation, diagnosis, treatment, outcome and its relation to CD4 count, a cross-sectional study in a tertiary care hospital in coastal Karnataka.J. Family Med. Prim. Care2020921160116510.4103/jfmpc.jfmpc_950_1932318485
     [Google Scholar]
  12. PawlowskiA. JanssonM. SköldM. RottenbergM.E. KälleniusG. Tuberculosis and HIV co-infectionPLoS Pathog201282e100246410.1371/journal.ppat.1002464
     [Google Scholar]
  13. RambaranS. MasekoT.G. LewisL. Hassan-MoosaR. ArcharyD. NgcapuS. GarrettN. McKinnonL.R. PadayatchiN. NaidooK. SivroA. Blood monocyte and dendritic cell profiles among people living with HIV with mycobacterium tuberculosis co-infection.BMC Immunol.20232412110.1186/s12865‑023‑00558‑z37480005
     [Google Scholar]
  14. LepardM. YangJ.X. AfkhamiS. NazliA. ZganiaczA. TangS. ChoiM.W.Y. VahediF. DeshiereA. TremblayM.J. XingZ. KaushicC. GillgrassA. Comparing current and next-generation humanized mouse models for advancing HIV and HIV/Mtb co-infection studies.Viruses2022149192710.3390/v1409192736146734
     [Google Scholar]
  15. PradoT.N. RajanJ.V. MirandaA.E. DiasE.S. CosmeL.B. PossueloL.G. SanchezM.N. GolubJ.E. RileyL.W. MacielE.L. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis.Braz. J. Infect. Dis.201721216217010.1016/j.bjid.2016.11.00627936379
     [Google Scholar]
  16. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.2021Available from: https://www.who.int/publications/i/item/9789240031593
  17. International Council of Nurses TB GUIDELINES for Nurses in the Care and Control of Tuberculosis and Multi-Drug-Resistant Tuberculosis.International Council of Nurses,International Council of Nurses,Geneva (Switzerland)20153rd ed
     [Google Scholar]
  18. RameshK. GandhiS. RaoV. Clinical profile of human immunodeficiency virus patients with opportunistic infections: A descriptive case series study.Int. J. Appl. Basic Med. Res.20155211912310.4103/2229‑516X.15716626097820
     [Google Scholar]
  19. GuptaP.K. SaxenaA. HIV/AIDS: Current updates on the disease, treatment and prevention.Proc. Natl. Acad. Sci., India, Sect. B Biol. Sci.202191349551010.1007/s40011‑021‑01237‑y33907349
     [Google Scholar]
  20. BalthazarM.S. Methods and approaches to hiv prevention.J. Assoc. Nurses AIDS Care2017281192410.1016/j.jana.2016.09.00527751633
     [Google Scholar]
  21. Combination Prevention2022Available from: https://avac.org/resource/combination-prevention-integrating-strategies-to-end-the-epidemic/
  22. CoatesT.J. RichterL. CaceresC. Behavioural strategies to reduce HIV transmission: How to make them work better.Lancet2008372963966968410.1016/S0140‑6736(08)60886‑718687459
     [Google Scholar]
  23. GanatraS.R. BucşanA.N. AlvarezX. KumarS. ChatterjeeA. QuezadaM. FishA. SinghD.K. SinghB. SharanR. LeeT.H. ShanmugasundaramU. VeluV. KhaderS.A. MehraS. RengarajanJ. KaushalD. Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model.J. Clin. Invest.2020130105171517910.1172/JCI13650232544085
     [Google Scholar]
  24. SharmaD. SharmaV. WangZ. Knowledge domain and emerging trends in HIV-MTB co-infection from 2017 to 2022: A scientometric analysis based on VOSviewer and CiteSpace.Front Public Health2023 111044426
     [Google Scholar]
  25. TabarsiP. ChitsazE. MoradiA. BaghaeiP. FarniaP. MarjaniM. ShamaiM. AmiriM. NikaeinS. MansouriD. MasjediM. AlticeF. Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.Int. J. STD AIDS2012239e1e410.1258/ijsa.2009.00909323033530
     [Google Scholar]
  26. SeliminD.S. IsmailA. AhmadN. IsmailR. Mohd AzmanN.F. AzmanA. Tuberculosis treatment outcome in patients with tb-hiv coinfection in kuala lumpur, malaysia.J. Trop. Med.2021202111010.1155/2021/992337834194511
     [Google Scholar]
  27. GoncharovaO. AbrahamyanA. NairD. BeglaryanM. BekbolotovA. ZhdanovaE. KadyrovA. ZachariahR. Triple Priority: TB/HIV co-infection and treatment outcomes among key populations in the kyrgyz republic: A national cohort study (2018–2022).Trop. Med. Infect. Dis.20238734210.3390/tropicalmed807034237505638
     [Google Scholar]
  28. KasibanteJ. RutakingirwaM.K. KagimuE. SsebambuliddeK. EllisJ. TugumeL. MpozaE. CresswellF. MeyaD.B. Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician’s perspective.J. Clin. Tuberc. Other Mycobact. Dis.20202010018010.1016/j.jctube.2020.10018032875123
     [Google Scholar]
  29. Salazar-AustinN. DowdyD.W. ChaissonR.E. GolubJ.E. Seventy years of tuberculosis prevention: Efficacy, effectiveness, toxicity, durability, and duration.Am. J. Epidemiol.2019188122078208510.1093/aje/kwz17231364692
     [Google Scholar]
  30. KielmannK. KaratA.S. ZwamaG. ColvinC. SwartzA. VoceA.S. YatesT.A. MacGregorH. McCreeshN. KallonI. VassallA. GovenderI. SeeleyJ. GrantA.D. Tuberculosis infection prevention and control: Why we need a whole systems approach.Infect. Dis. Poverty2020915610.1186/s40249‑020‑00667‑632450916
     [Google Scholar]
  31. WellsC.D. CegielskiJ.P. NelsonL.J. LasersonK.F. HoltzT.H. FinlayA. CastroK.G. WeyerK. HIV infection and multidrug-resistant tuberculosis: The perfect storm.J. Infect. Dis.2007196s1Suppl. 1S86S10710.1086/51866517624830
     [Google Scholar]
  32. StephensF. GandhiN.R. BrustJ.C.M. MlisanaK. MoodleyP. AllanaS. CampbellA. ShahS. Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa.J. Acquir. Immune Defic. Syndr.201982212413010.1097/QAI.000000000000212031513073
     [Google Scholar]
  33. MartinsonN.A. BarnesG.L. MoultonL.H. MsandiwaR. HauslerH. RamM. McIntyreJ.A. GrayG.E. ChaissonR.E. New regimens to prevent tuberculosis in adults with HIV infection.N. Engl. J. Med.20113651112010.1056/NEJMoa100513621732833
     [Google Scholar]
  34. PeloquinC.A. DaviesG.R. The Treatment of Tuberculosis.Clin. Pharmacol. Ther.202111061455146610.1002/cpt.226133837535
     [Google Scholar]
  35. GillC. M. DolanL. PiggottL. M. McLaughlinA. M. New developments in tuberculosis diagnosis and treatmentEur Respir Soc202218121014910.1183/20734735.0149‑2021
     [Google Scholar]
  36. GobleM. IsemanM.D. MadsenL.A. WaiteD. AckersonL. HorsburghC.R.Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.N. Engl. J. Med.1993328852753210.1056/NEJM1993022532808028426619
     [Google Scholar]
  37. DartoisV. A. RubinE. J. Anti-tuberculosis treatment strategies and drug development: Challenges and prioritiesNat Rev Microbiol2022201168570110.1038/s41579‑022‑00731‑y
     [Google Scholar]
  38. LuetkemeyerA.F. GetahunH. ChamieG. LienhardtC. HavlirD.V. Tuberculosis drug development: Ensuring people living with HIV are not left behind.Am. J. Respir. Crit. Care Med.2011184101107111310.1164/rccm.201106‑0995PP21868507
     [Google Scholar]
  39. VasiliuA. Tuberculosis prevention: Current strategies and future directions.Clin. Microbiol. Infect.2023Oct10.1016/j.cmi.2023.10.02337918510
     [Google Scholar]
  40. DhameliyaT. M. BhakharK. A. GajjarN. D. PatelK. A. DevaniA. A. HiraniR. V. Recent advancements and developments in search of anti-tuberculosis agents: A quinquennial update and future directionsJ Mol Struct.2022124813147310.1016/j.molstruc.2021.131473
     [Google Scholar]
  41. ScribaT.J. CoussensA.K. FletcherH.A. Human Immunology of Tuberculosis.Microbiol. Spectr.2017515.1.1510.1128/microbiolspec.TBTB2‑0016‑201628155806
     [Google Scholar]
  42. Tuberculosis control in migrant populations guiding principles and proposed actions.2016Available from: https://www.who.int/publications/i/item/9789290617754
    [Google Scholar]
  43. AlemuA. Wubie AychehM. DilnessaT. Tuberculosis and human immunodeficiency virus co-infection and associated factors at debre markos comprehensive specialized hospital, northwest ethiopia: A four-year retrospective studyHIV AIDS (Auckl)20211329329910.2147/HIV.S284034
     [Google Scholar]
/content/journals/cis/10.2174/012210299X324303241009061805
Loading
HIV-TB Coinfection: A Systemic Review and Meta-analysis Insights
Curr. Indian Sci. 2, e2210299X324303 (2024); https://doi.org/10.2174/012210299X324303241009061805
/content/journals/cis/10.2174/012210299X324303241009061805
/content/journals/cis/10.2174/012210299X324303241009061805
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): CD4+ cells; Coinfection; Drug resistance; HIV; Latent TB; MTB

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test